纳武利尤单抗在老年晚期肺鳞癌患者中的应用:意大利扩展准入项目队列结果
该分析评估纳武利尤单抗在意大利扩展准入项目中晚期肺鳞癌老年患者的疗效与安全性。共纳入371例患者,按年龄<65、65-<75和≥75岁分组。各年龄组客观缓解率和疾病控制率相似,≥75岁组中位总生存期较短(5.8个月),3-4级治疗相关不良事件发生率低(3%-9%),因不良事件停药率低(4%-5%)。结论提示老年晚期肺鳞癌患者可从纳武利尤单抗获益,耐受性与总体人群相似。
要点
- 各年龄组客观缓解率相似(18%-19%),疾病控制率43%-49%。
- ≥75岁患者中位总生存期5.8个月,短于<65岁组的8.6个月。
- 3-4级治疗相关不良事件发生率低(3%-9%),停药率4%-5%。
核心结论
- 老年晚期肺鳞癌患者可从纳武利尤单抗治疗中获益,耐受性与总体人群相似。
研究设计与样本
- 意大利扩展准入项目(EAP)队列分析,共纳入371例晚期肺鳞癌患者,按年龄<65、65-<75和≥75岁分组。
主要发现
- 各年龄组客观缓解率分别为18%、18%、19%,总体18%;疾病控制率分别为49%、47%、43%,总体47%。
- ≥75岁组中位总生存期5.8个月,<65岁组8.6个月,65-<75岁组8.0个月,总体7.9个月。
- 3-4级治疗相关不良事件发生率分别为3%、9%、3%,总体6%;因治疗相关不良事件停药率4-5%。
临床怎么用
- 老年晚期肺鳞癌患者可考虑使用纳武利尤单抗,但需关注≥75岁患者可能较短的生存期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: This analysis evaluated the efficacy and safety of nivolumab, an immune checkpoint inhibitor, in elderly patients with stage IIIB or IV squamous non-small-cell lung cancer (NSCLC) enrolled in the expanded access programme (EAP) in Italy. METHODS: Nivolumab was available on physician request. Safety data included adverse events (AEs). Efficacy data included investigator-assessed tumour response, progression date and survival information. Results were analysed for patients aged <65, 65-<75 and ≥75 years and for the overall population. RESULTS: A total of 371 patients with squamous NSCLC were enrolled at 96 centres between April 2015 and September 2015; 34% (n = 126), 47% (n = 175) and 19% (n = 70) were aged <65, 65-<75 and ≥75 years, respectively. Efficacy was similar among patients aged <65, 65-<75 and ≥75 years and the overall population (objective response rates: 18%, 18%, 19% and 18%, respectively; disease control rates: 49%, 47%, 43% and 47%, respectively). Median overall survival was reduced in patients aged ≥75 years (5.8 months) versus patients aged <65; years (8.6 months), patients aged 65-<75 years (8.0 months) and the overall population (7.9 months). The incidence of grade 3-4 treatment-related AEs was low in patients aged 65, 65-<75 and ≥75 years and the overall population (3%, 9%, 3%, 6%, respectively). Discontinuation rates due to treatment-related AEs were low irrespective of age (4-5%). CONCLUSIONS: These EAP results suggest that elderly patients with advanced squamous NSCLC benefit from nivolumab, with tolerability similar to that in the overall population.
引用
- Grossi F, Crinò L, Logroscino A, et al. Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. Eur J Cancer. 2018. PMID: 30014881. doi:10.1016/j.ejca.2018.05.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。